TENAX THERAPEUTICS, INC.
TENXDrugs in Pipeline
4
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Oct 15, 2026
32wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
TNX-103
Pulmonary Hypertension
Levosimendan
Hypertension Pulmonary Secondary
perfluorocarbon emulsion (Oxycyte) infusion
Traumatic Brain Injury
Levosimendan 2.5 mg/ml Injectable Solution
Hypertension Pulmonary Secondary Heart Failure
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
TNX-103 | Phase 3 | Pulmonary Hypertension | - | - |
Levosimendan | Phase 2 | Hypertension Pulmonary Secondary | - | - |
perfluorocarbon emulsion (Oxycyte) infusion | Phase 2 | Traumatic Brain Injury | - | - |
Levosimendan 2.5 mg/ml Injectable Solution | Phase 2 | Hypertension Pulmonary Secondary Heart Failure | - | - |
Hypertension Pulmonary Secondary
1 drug in this indication
Traumatic Brain Injury
1 drug in this indication
Hypertension Pulmonary Secondary Heart Failure
1 drug in this indication
Pulmonary Hypertension
1 drug in this indication
Coronary Artery Bypass Grafting
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)